维生素C联合非布司他对高尿酸血症伴痛风患者sICAM-1及尿酸的影响

Effects of Vitamin C Combined with Febuxostat on sICAM-1 and Uric Acid in Patients with Hyperuricemia and Gout

目的探讨维生素C联合非布司他对高尿酸血症伴痛风患者血清可溶性细胞间粘附分子-1(sICAM-1)及尿酸的影响。方法选取我院2018年4月~2019年4月收治的78例高尿酸血症伴痛风患者,采用随机数字表法分为观察组以及对照组,各39例。两组均予以痛风定胶囊口服治疗,对照组在此基础上给予维生素C+别嘌呤醇口服治疗,观察组在此基础上给予维生素C+非布司他口服治疗,比较两组炎症因子[肿瘤坏死因子-α(TNF-α)、sICAM-1]水平、尿酸水平、氧化应激反应指标[晚期氧化蛋白产物(AOPP)、丙二醛(MDA)、血清超氧化物歧化酶(SOD)]水平及不良反应。结果两组治疗6个疗程后TNF-α、sICAM-1、尿酸水平均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组治疗前AOPP、MDA、SOD水平比较,差异无统计学意义(P>0.05),两组治疗6个疗程后AOPP、MDA水平较治疗前降低,SOD水平较治疗前升高,且观察组AOPP、MDA水平低于对照组,SOD水平高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为12.82%,低于对照组的7.69%,差异无统计学意义(P>0.05)。结论高尿酸血症伴痛风患者采用维生素C联合非布司治疗可有效降低炎性因子与尿酸水平,减轻机体氧化应激反应,且不会增加不良反应。

Objective To investigate the effect of vitamin C combined with febuxostat on serum soluble intercellular adhesion molecule-1(sICAM-1)and uric acid in patients with hyperuricemia and gout.Methods 78 patients with hyperuricemia and gout treated in our hospital from April 2018 to April 2019 were selected and divided into observation group and control group with random number table method,39 cases in each.Both groups were given oral treatment of Tongfengding capsules,and the control group was given oral treatment of vitamin C+allopurinol,and the observation group was given oral treatment of vitamin C+febuxostat on this basis,comparing inflammatory factors[tumor necrosis factor-α(TNF-α),sICAM-1]level,uric acid level,oxidative stress response index[late oxidation protein product(AOPP),malondialdehyde(MDA),serum superoxide dismutase(SOD)]level and Adverse reactions.Results After 6 courses of treatment,the levels of TNF-α,sICAM-1 and uric acid in the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05),Before treatment,the levels of AOPP,MDA,and SOD between the two groups were not statistically significant(P>0.05).After 6 courses of treatment,the levels of AOPP and MDA of the two groups were lower than before treatment,and the levels of SOD were higher than before treatment.AOPP and MDA levels were lower than the control group,SOD levels were higher than the control group,the difference was statistically significant(P<0.05),the incidence of adverse reactions in the observation group was 12.82%,lower than 7.69%in the control group,the difference was not statistically significant(P>0.05).Conclusion The treatment of hyperuricemia with gout patients with vitamin C combined with febuxostat can effectively reduce the levels of inflammatory factors and uric acid,reduce the body's oxidative stress response,and will not increase adverse reactions.